Analysts expect DexCom, Inc. (NASDAQ:DXCM) to report earnings of $0.09 per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for DexCom’s earnings, with estimates ranging from ($0.08) to $0.22. DexCom posted earnings per share of ($0.05) during the same quarter last year, which indicates a positive year over year growth rate of 280%. The company is expected to announce its next earnings report on Wednesday, May 6th.
On average, analysts expect that DexCom will report full year earnings of $1.81 per share for the current year, with EPS estimates ranging from $1.02 to $2.64. For the next financial year, analysts expect that the firm will report earnings of $2.67 per share, with EPS estimates ranging from $2.07 to $3.43. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover DexCom.
DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $1.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.41. The company had revenue of $462.80 million for the quarter, compared to analyst estimates of $457.00 million.
DexCom stock traded up $31.70 during trading hours on Friday, hitting $283.91. 3,314,206 shares of the company traded hands. The firm’s 50-day simple moving average is $234.38 and its two-hundred day simple moving average is $190.54. DexCom has a 1-year low of $107.44 and a 1-year high of $295.00.
In other news, SVP Patrick Michael Murphy sold 500 shares of DexCom stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $235.01, for a total value of $117,505.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $242.39, for a total transaction of $1,454,340.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,427 shares of company stock worth $10,539,425. 1.80% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC boosted its holdings in shares of DexCom by 4.9% during the third quarter. Voya Investment Management LLC now owns 1,306,570 shares of the medical device company’s stock worth $194,992,000 after purchasing an additional 61,506 shares during the period. Blair William & Co. IL boosted its holdings in shares of DexCom by 4.9% during the fourth quarter. Blair William & Co. IL now owns 1,205,089 shares of the medical device company’s stock worth $263,601,000 after purchasing an additional 56,352 shares during the period. Fred Alger Management LLC boosted its holdings in shares of DexCom by 66.3% during the fourth quarter. Fred Alger Management LLC now owns 752,206 shares of the medical device company’s stock worth $164,538,000 after purchasing an additional 299,754 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of DexCom by 1,164.0% during the fourth quarter. Renaissance Technologies LLC now owns 700,243 shares of the medical device company’s stock worth $153,171,000 after purchasing an additional 644,843 shares during the period. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of DexCom by 5.3% during the fourth quarter. Westfield Capital Management Co. LP now owns 612,124 shares of the medical device company’s stock worth $133,896,000 after purchasing an additional 30,671 shares during the period. 97.85% of the stock is currently owned by institutional investors and hedge funds.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.